Skip to main content

Table 2. Antiangiogenetic therapies for patients newly diagnosed with ovarian cancer

From: Ovarian cancer standard of care: are there real alternatives?

Therapy Agent Trial Number of patients Armsa Primary endpoint Results
Combination with chemotherapy Bevacizumab GOG218[41] 1,873 CP × 6 + Pl → Pl PFS Prolonged PFS, max PFS benefit (Pl group vs. Bm group, 18 vs. 12 months, hazard ratio = 0.64, P < 0.001)
CP × 6 + B (15 mg/m2)
CP × 6 + B→Bm (15 mg/m2)
   ICON7[42] 1,528 CP × 6 PFS Prolonged PFS (17.3 vs. 19 months, P = 0.004)
CPB × 6→Bm (7.5 mg/m2)
  Nintedanib AGO-OVAR 12[57] 1,366 CP × 6 PFS Prolonged PFS (16.6 vs. 17.3 months, P = 0.024)
CPB × 6 + N
Maintenance Pazopanib AGO-OVAR 16[54] 940 CP × 5 → Pl PFS Prolonged PFS (12.3 vs. 17.9 months, P = 0.002)
CP × 5 → Paz m
  1. a “x n” means “for n cycles of chemotherapy.” CP: carboplatin AUC 5 mg/mL per minute and paclitaxel 175 mg/m2 every 3 weeks; Pl: placebo; B: bevacizumab; Bm: bevacizumab maintenance; PFS: progression-free survival; N: nintedanib; Paz m: pazopanib maintenance.